NeuroPace (NPCE) EBIT Growth (1y) (2021 - 2026)
NeuroPace (NPCE) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | -17.50% |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 49.06% |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 43.83% |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 24.81% |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 49.72% |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 13.00% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 57.74% |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 16.18% |
| 10 | NeuroPace | 469.45 Mn | 417.75 Mn | 18.91 Mn | 37.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.20% |
| Mar 31, 2026 | -8.18% |
| Dec 31, 2025 | 51.63% |
| Sep 30, 2025 | 38.72% |
| Jun 30, 2025 | -9.53% |
| Mar 31, 2025 | 31.78% |
| Dec 31, 2024 | 27.68% |
| Sep 30, 2024 | 28.69% |
| Jun 30, 2024 | 20.68% |
| Mar 31, 2024 | 9.30% |
| Dec 31, 2023 | 48.77% |
| Sep 30, 2023 | 41.66% |
| Jun 30, 2023 | 28.43% |
| Mar 31, 2023 | 14.78% |
| Dec 31, 2022 | -9.36% |
| Sep 30, 2022 | -63.37% |
| Jun 30, 2022 | -138.31% |
| Mar 31, 2022 | -151.99% |
| Dec 31, 2021 | -202.42% |
| Sep 30, 2021 | -435.42% |